An interventional study of Non-ketogenic Diet and Ketogenic Diet in Bipolar Disorder, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Pittsburgh · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Bipolar Disorder by University of Pittsburgh — 1 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · University of Pittsburgh.
Among the 22 studies in Bipolar Disorder by University of Pittsburgh, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 21st registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →1 of the 22 studies in Bipolar Disorder by University of Pittsburgh is open now, in 1 country.
By country, each count listing its studies:
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4 · Phase 4 2
First in 1994; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 107 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 53 across the 19 interventional studies, 123 across the 2 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pittsburgh is the lead sponsor of 1,422 studies on the registry; 170 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
2 of the studies in Bipolar Disorder by University of Pittsburgh that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04815239University of PittsburghEarly Intervention for Youth at High Risk for Bipolar Disorder | 2027-04-30 |
| NCT06081426University of PittsburghExamining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD) | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Bipolar Disorder by University of Pittsburgh, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).
The investigators hypothesize that a ketogenic diet will enhance levels of the ketone body β-Hydroxybutyrate (beta OHB), resulting in reduced mania/hypomania severity and predisposition to mania/hypomania in individuals with BD. To test this hypothesis in depth, the investigators will use a novel, multidisciplinary mechanistic study using multimodal neuroimaging, peripheral markers of mitochondrial metabolism, and participant-derived induced pluripotent stem cell (iPSC)-derived organoids.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants:
BD hypomanic group (n=30):
BD euthymic group (n=30):
Healthy Control (HC) Group (n=30):
Exclusion Criteria:
All participants:
BD hypomanic group:
BD euthymic group:
Healthy Control (HC) Group
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Bipolar Disorder will consume a non-ketogenic diet for the first phase of the study and then a ketogenic diet for the second phase of the study
Other: Non-ketogenic Diet · Other: Ketogenic Diet
Participants with Bipolar Disorder will consume a ketogenic diet for the first phase of the study and then a non-ketogenic diet for the second phase of the study
Other: Non-ketogenic Diet · Other: Ketogenic Diet
Participants without Bipolar Disorder will not participate in the diet phases of the study
Other: No diet
Consuming a non-ketogenic diet
Consuming a ketogenic diet
Participants without Bipolar Disorder will not participate in the diet phases of the study
Blood oxygen level-dependent (BOLD) signal at Scan 1
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity
Time frame: Baseline Scan 1 (all participants)
Blood oxygen level-dependent (BOLD) signal at Scan 2
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Blood oxygen level-dependent (BOLD) signal at Scan 3
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Manic symptoms at Scan 1
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)
Time frame: Baseline Scan 1 (all participants)
Manic symptoms at Scan 2
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)
Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Manic symptoms at Scan 3
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)
Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting Glucose at Baseline
Fasting glucose blood levels
Time frame: Baseline (all participants)
Fasting lipids at Baseline
Fasting lipid blood levels
Time frame: Baseline (all participants)
Fasting hepatic function panel at Baseline: total protein
Fasting levels of total protein in the blood
Time frame: Baseline (all participants)
Fasting hepatic function panel at Baseline: albumin
Fasting levels of albumin in the blood
Time frame: Baseline (all participants)
Fasting hepatic function panel at Baseline: bilirubin
Fasting levels of bilirubin in the blood
Time frame: Baseline (all participants)
Fasting hepatic function panel at Baseline: liver enzyme
Fasting levels of liver enzyme in the blood
Time frame: Baseline (all participants)
Fasting Glucose at halfway point through first dietary phase
Fasting glucose blood levels
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting lipids at halfway point through first dietary phase
Fasting lipid blood levels
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: total protein
Fasting levels of total protein in the blood
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: albumin
Fasting levels of albumin in the blood
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: bilirubin
Fasting levels of bilirubin in the blood
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: liver enzyme
Fasting levels of liver enzyme in the blood
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting Glucose at end of first dietary phase
Fasting glucose blood levels
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting lipids at end of first dietary phase
Fasting lipid blood levels
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: total protein
Fasting levels of total protein in the blood
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: albumin
Fasting levels of albumin in the blood
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: bilirubin
Fasting levels of bilirubin in the blood
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: liver enzyme
Fasting levels of liver enzyme in the blood
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting Glucose at halfway point through second dietary phase
Fasting glucose blood levels
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting lipids at halfway point through second dietary phase
Fasting lipid blood levels
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: total protein
Fasting levels of total protein in the blood
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: albumin
Fasting levels of albumin in the blood
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: bilirubin
Fasting levels of bilirubin in the blood
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: liver enzyme
Fasting levels of liver enzyme in the blood
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting Glucose at end of second dietary phase
Fasting glucose blood levels
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting lipids at end of second dietary phase
Fasting lipids blood levels
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: total protein
Fasting levels of total protein in the blood
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: albumin
Fasting levels of albumin in the blood
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: bilirubin
Fasting levels of bilirubin in the blood
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: liver enzyme
Fasting levels of liver enzyme in the blood
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Gamma-aminobutyric acid (GABA) at Baseline
Gamma-aminobutyric acid (GABA) concentrations in the brain
Time frame: Baseline Scan 1 (all participants)
Glutamate at Baseline
Glutamate concentrations in the brain
Time frame: Baseline Scan 1 (all participants)
Lactate at Baseline
Lactate concentrations in the brain
Time frame: Baseline Scan 1 (all participants)
Gamma-aminobutyric acid (GABA) at end of first dietary phase
Gamma-aminobutyric acid (GABA) concentrations in the brain
Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Glutamate at end of first dietary phase
Glutamate concentrations in the brain
Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Lactate at end of first dietary phase
Lactate concentrations in the brain
Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Gamma-aminobutyric acid (GABA) at end of second dietary phase
Gamma-aminobutyric acid (GABA) concentrations in the brain
Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Glutamate at end of second dietary phase
Glutamate concentrations in the brain
Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Lactate at end of second dietary phase
Lactate concentrations in the brain
Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Average total sleep time during Ketogenic vs Normal diet
Total sleep time will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home.
Time frame: Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals
Average rest-activity rhythm interdaily stability during Ketogenic vs Normal diet
Rest-activity rhythm interdaily stability will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home
Time frame: Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.
Ecological momentary assessments (EMA) during the first dietary phase: Mood monitoring
Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood
Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the first dietary phase: Energy monitoring
Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy
Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the first dietary phase: Suicidality monitoring
Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans
Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Mood monitoring
Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood
Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Energy monitoring
Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy
Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Suicidality monitoring
Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans
Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Plan to share: Yes — Informed consent will be collected from study participants that allows for broad sharing of participants' de-identified data. Data transfer procedures will be in accordance with all Institutional Review Board guidelines and federal regulations including HIPAA (Health Insurance Portability and Accountability Act of 1996).
Time frame: The principal investigators (PIs) reserve the right to publish on the stated aims in a timely manner. Data will be available for addressing other research questions (i.e. which are not described in funded/pending grants) as soon as the data have been checked for accuracy (a period which will be no later than one year after the completion of each assessment). After the study has ended, the study investigators will continue to test the stated aims, but will also continue to solicit collaborations with outside researchers and to consider data requests in a timely manner.
Access criteria: Outside investigators must submit a 1)proposal of the study aims, hypotheses, variables/constructs, analytic approach, and estimated duration of the proposed research; 2)resume, qualifications, source of financial support, and conflict of interest statement; 3)sign a data-sharing agreement and confidentiality statement that stipulates using the data for the stated research purposes only, securing the data using appropriate computer technology, not manipulating the data in order to identify participants, acknowledging the grant that supported data collection and management in publications/presentations, and destroying or returning the data after analyses are complete; 4)obtain approval from their Institutional Review Board, and along with other staff members who have access to the data, submit certificates of the University of Pittsburgh Education and Certification Program in Research Practice Fundamentals or provide written documentation of similar human subjects protection training.
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.
Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 41 months is above that.
Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2027 → Jun 2027 and completion Jan 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.